Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from ¿ìè¶ÌÊÓƵ
Explore the latest news, articles and features
Popular articles
Trending ¿ìè¶ÌÊÓƵ articles
1
The best new science-fiction books of June 2026
2
Pancreatic cancer halted by virus injection in three patients
3
Glaciers in the 'roof of the world' have suddenly started melting
4
Does gravity create reality? A shocking path to a theory of everything
5
Mathematical AI helps researchers crack 50-year-old problem
6
Aim high but don't shoot for the moon, mathematicians advise
7
How a radical new view of life could reveal its origin – and aliens
8
Photons behave very strangely if you try to cut them
9
Virus from marine animals is causing weird eye problems in people
10
Earliest use of anaesthetics uncovered in Chinese doctor’s tomb
